Pharmacokinetic and pharmacodynamic modelling of antibiotic therapy

Current Opinion in Infectious Diseases

Volumn 11, Issue 6, 1998, Pages 673-680

  Moise, Pamela A ^a   Schentag, Jerome J ^a  

^a MILLARD FILLMORE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN; ANTIBIOTIC AGENT; CEFEPIME; CEFMENOXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; TELITHROMYCIN; TOBRAMYCIN; TROVAFLOXACIN; VANCOMYCIN;

AREA UNDER THE CURVE; ARTICLE; DRUG EFFICACY; INFECTION; MINIMUM INHIBITORY CONCENTRATION; MODEL;

EID: 0032436367     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199812000-00005     Document Type: Article

References (42)

1. Craig WA, Redington J, Ebert SC. Pharmacodynamics of amikacin in vitro and in mouse thigh infections. J Antimicrob Chemother 1991; 27:29-40.
2. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 158:831-847.
3. Leggett JE, Fantin B, Ebert S, Totsuka K, Vogelman B, Calame W, et al. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh infection models. J Infect Dis 1989; 159:281-292.
4. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rational for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26:1-10.
5. Dudley MN. Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones. Am J Med 1991; 91:45S-50S.
6. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to MIC. J Infect Dis 1987; 155:93-99.
7. Drusano GL. Human pharmacodynamics of beta lactams, aminoglycosides, and their combination. Scand J Infect Dis 1991; 74:235-248.
8. Lode H, Borner K, Koeppe P. Pharmacodynamics of fluoroquinolones. Clin Infect Dis 1998; 27:33-39.
9. Lacy MK, Nicolau , Nightingale CH, Quintiliani R. The pharmacodynamics of aminoglycosides. Clin Infect Dis 1998; 27:23-27.
10. Turnidge JD. The pharmacodynamics of β-lactams. Clin Infect Dis 1998; 27:10-22.
11. Drusano GL, Johnson DE, Rosen M, Standiford HC. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993; 37:483-490.
12. Schentag JJ, Nix DE, Adelman MH. Mathematical examination of dual individualization principles (I). Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. Ann Pharmacother 1991; 25:1050-1057.
13. Goss TF, Forrest A, Nix DE, Ballow CH, Birmingham MC, Cumbo TJ. Mathematical examination of dual individualization principles (II). The rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmonoxime. Ann Pharmacother 1994; 28:863-868.
14. Luzier A, Goss TF, Cumbo TJ, Schentag JJ. Mathematical examination of dual individualization principles (III). Development of a scoring system for pneumonia staging and quantitation of response to antibiotics: results in cefmenoxime treated patients. Ann Pharmacother 1992; 26:1358-1364.
15. Hyatt JM, McKinnon PS, Zimmer GZ, Schentag JJ. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome: focus on antibacterial agents. Clin Pharmacokinet 1995; 28:143-160.
16. Amsden GW, Ballow CH, Schentag JJ. Population pharmacokinetic methods to optimize antibiotic effects. Drug Invest 1993; 5:256-268.
17. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37:1073-1081.
18. Schentag JJ, Reitberg DP, Cumbo TJ. Cefmonoxime efficacy, safety, and pharmacokinetics in critical care patients with nosocomial pneumonia. Am J Med 1984; 77:34-42.
19. Schentag JJ, Smith IL, Swanson DJ, DeAngelis C, Fracasso JE, Vari A, Vance JW. Role for dual individualization with cefmenoxime. Am J Med 1984; 77:43-50.
20. Forrest A, Ballow CH, Nix DE, Birmingham MC, Schentag JJ. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother 1993; 37:1065-1072.
21. Paladino JA, Fell RE. Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial pneumonia. Ann Pharmacother 1994; 28:384-389.
22. McKinnon PS. Paladino JA, Schentag JJ. Evaluation of AUC/MIC and time above the MIC as predictors of outcome for advanced-generation cephalosporins in serious bacterial infections [abstract A-58]. In: Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco. Washington, DC: American Society for Microbiology; 1995.
23. Schentag JJ, Nix DE, Forrest A, Adelman MH. The universal parameter within the constraint of a reasonable dosing interval. Ann Pharmacother 1996; 30:1029-1031.
24. Den Hollander JG, Mouton JW, Verbrugh HA. Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics. Antimicrob Agents Chemother 1998; 42:744-748. This paper describes predictors of response for combination therapy with tobramycin and ceftazidime in vitro.
25. Firsov AA, Shevchenko AA, Vostrov SN, Zinner SH. Inter-and intraquinolone predictors of antimicrobial effect in an in-vitro dynamic model: new insight into a widely used concept. Antimicrob Agents Chemother 1998; 42:659-665. This article describes PK/PD indices the investigators found to be predictors of the antimicrobial effects of trovafloxacin and ciprofloxacin.
26. Dalla Costa T, Nolting A, Rand K, Derendorf H. Pharmacokinetic-pharmacodynamic modelling of the in-vitro anti-infective effect of piperacillin-tazobactam combinations. Int J Clin Pharmacol Ther 1997; 35:426-433. This paper examines the effects of various piperacillin-tazobactam dose ratio combinations and dosing regimens against E. coli in an in-vitro model.
27. Houlihan HH, Mercier RC, Rybak MJ. Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in-vitro infection model. Antimicrob Agents Chemother 1997; 41:2497-2501. The pharmacodynamics of various vancomycin regimens with or without one of two gentamicin regimens are analysed in an in-vitro model with MRSA-infected fibrin-platelet clots.
28. Boswell FJ, Andrews JM, Wise R. Pharmacodynamic properties of HMR 3647, a novel ketolide, on respiratory pathogens, enterococci and Bacteroides fragilis demonstrated by studies of time-kill kinetics and postantibiotic effect. J Antimicrob Chemother 1998; 41:149-153. This article explores the pharmacodynamics of a ketolide, a new class of macrolide antibiotics.
29. Chavanet P, Dalle F, Delisle P, Duong M, Pechinot A, Buisson M, et al. Experimental efficacy of combined ceftriaxone and amoxycillin on penicillin-resistant and broad-spectrum cephalosporin-resistant Streptococcus pneumoniae infection. J Antimicrob Chemother 1998; 41:237-246. PK/PD indices correlating with the efficacy of amoxicillin and ceftriaxone in vitro and in an animal model are described.
30. Mimoz O, Jacolot A, Padoin C, Tod M, Samii K, Petitjean O. Cefepime and amikacin synergy in vitro and in vivo against a ceftazidime-resistant strain of Enterobacter cloacae. J Antimicrob Chemother 1998; 41:367-372. This paper examines the response of Enterobacter cloacae to cefepime and amikacin monotherapy and in combination.
31. Chow JW, Fine MJ, Schlaes DM, Quinn JP, Hooper DC, Johnson MP, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115:585-590.
32. Sanders CC, Sanders WE. Beta lactam resistance in Gram-negative bacteria. Global trends and clinical impact. Clin Infect Dis 1992; 15:824-839.
33. Thomas JK, Forrest A, Bhavnani SM, Hyatt JM, Cheng A, Ballow CH, Schentag JJ. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42:521-527. An important paper examining the relationship of antibiotic exposure, activity and other variables associated with bacterial resistance. These variables are used to develop a PK/PD model describing PK/PD indices and an AUIC24 breakpoint associated with the development of resistance in the patient population being studied.
34. Hyatt JM, Luzier AB, Forrest A, Ballow CH, Schentag JJ. Modeling the response of pneumonia to antimicrobial therapy. Antimicrob Agents Chemother 1997; 41:1269-1274. A good correlation was obtained between a clinical pneumonia scoring system and bacterial response to antibiotics.
35. Kashuba AD, Bertino JS, Nafziger AN. Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by Gram-negative organisms. Antimicrob Agents Chemother 1998; 42:1842-1844.
36. Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, et al. Pharmacodynamics of levofloxacin. A new paradigm for early clinical trials. JAMA 1998; 279:125-129. An excellent example of PK/PD modelling of levofloxacin in humans. This is one of the few prospective clinical trials published within the past year that analyses this concept in a patient population of over 300.
37. Occhipinti DJ, Pendland SL, Schoonover LL, Rypins EB, Danziger LH, Rodvold KA. Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens. Antimicrob Agents Chemother 1997; 41:2511-2517.
38. Nix DE, Wilton JH, Hyatt J, Thomas J, Strenkoski-Nix LC, Forrest A, Schentag JJ. Pharmacodynamic modeling of the in-vivo interaction between cefotaxime and ofloxacin by using serum ultrafiltrate inhibitory titers. Antimicrob Agents Chemother 1997; 41:1108-1114. An interesting article examining the pharmacokinetic and pharmacodynamic interactions between cefotaxime and ofloxacin with the use of serum inhibitory titres.
39. Madaras-Kelly KJ, Ostergaard BE, Hovde LB, Rotschafer JC. Twentyfour hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in-vitro pharmacodynamic model. Antimicrob Agents Chemother 1996; 40:627-632.
40. Schentag JJ, Birmingham MC, Paladino JA, Carr JR, Hyatt JM, Forrest A, et al. In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance. Semin Respir Infect 1997; 12:278-293.
41. Hyatt JM, Nix DE, Schentag JJ. Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for with MICs are similar. Antimicrob Agents Chemother 1994; 38:2730-2737.
42. Barriere SL, Ely E, Kapusnik JE, Gambertoglio JG. Analysis of a new method for assessing activity of combinations of antimicrobials: area under the bactericidal curve. J Antimicrob Chemother 1985; 16:49-59.